Cytoagents inc
WebCytoAgents is developing a small molecule pharmaceutical to treat severe influenza. Our platform technology employs a well-studied compound, GP1681, that was found to be safe and well-tolerated in multiple clinical studies; but the compound had NOT been previously investigated as an influenza therapeutic. Notably, in animal WebCytoAgents, Inc Sep 2024 - Aug 2024 1 year. Pittsburgh, Pennsylvania, United States Chief Executive Officer ... Anequest, Inc. 1988 - 1989 1 year. Madison, Wisconsin Senior Product Group Manager ...
Cytoagents inc
Did you know?
WebApr 28, 2024 · About CytoAgents CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, influenza, viral infectious ... WebMar 16, 2024 · Contact MBO to learn more about our solutions for independent professionals and enterprises. MBO is the independent workforce management leader, …
WebHeadquarters. CytoAgents, Inc 100 S. Commons Suite 102 Pittsburgh, PA 15212 (412) 303-1200 [email protected] WebJun 20, 2024 · Hi, we’re CytoAgents, Inc. CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases. Where We Are. 100 S Commons Pittsburgh PA …
WebGet in touch. 45190 Prologis Plaza, Suite 165. Dulles , VA 20166USA. 703.478.6009 WebHow CTO1681 Works. CytoAgents’ drug candidate, CTO1681 (formerly GP1681), prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway and modulating cytokine production, resulting in reduced inflammation. NF-kB plays a critical role in the body’s natural regulation, activation, and differentiation of inflammatory ...
WebMar 6, 2024 · The outcomes of this project will prepare CytoAgents for an IND application for the use of GP1681 in the treatment of COVID-19. Public Health Relevance The current outbreak of SARS-CoV-2, a highly pathogenic CoV that causes lower respiratory tract infections and severe pneumonia, represents a severe public health emergency.
WebCytoAgents is developing an innovative solution for the treatment of symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, … unshackled radio broadcastWebFunding. CytoAgents has raised a total of $10.2M in funding over 9 rounds. Their latest funding was raised on Aug 11, 2024 from a Venture - Series Unknown round. CytoAgents is funded by 6 investors. Innovation Works and National Institutes of Health are the most recent investors. unshackled prisoner wineWebAbout GENCO Systems. GENCO Systems, Inc. was established in 1994 to provide the Federal Government and industry with superior professional services in engineering and … unshackled prisoner wine companyWebCytoAgents, Inc 1,036 followers on LinkedIn. Calming the Cytokine Storm, Rebalancing the Immune System. Accessible treatment for multiple areas of high unmet need. CytoAgents is a clinical ... unshackled radio dramaWebSep 7, 2024 · PITTSBURGH-- ( BUSINESS WIRE )-- CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. unshackled quartermasterWebCytoAgents, Inc 1,122 followers 11h Report this post Report Report. Back ... unshackled radio program 2023 scheduleWebJun 20, 2024 · CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza and other viral infectious diseases. Where We Are 100 S … unshackled purpose